

Datasheet for 200-502-L54

Ly-6G/Ly-6C (Gr-1) Fluorescein Antibody**Overview**

Description:	Anti-Ly-6G/Ly-6C (Gr-1) (RAT) Fluorescein Conjugated Monoclonal Antibody - 200-502-L54
Item No.:	200-502-L54
Size:	500 µg
Applications:	FC, Multiplex
Reactivity:	Mouse
Host Species:	Rat

Product Details

Background:	Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.
Synonyms:	Ly-6G/Ly-6C (Gr-1), RB6-8C5, Gr-1, Ly-6G, Ly-6C
Host Species:	Rat
Conjugate:	Fluorescein (FITC)
Clonality:	Monoclonal
Clone ID:	RB6-8C5
Format:	IgG2b
F/P Ratio:	4-6

Target Details

Gene Name:	Gr-1
Reactivity:	Mouse
Immunogen Type:	Other

Immunogen:	Anti-Ly-6G/Ly-6C (Gr-1) Antibody (Monoclonal) was produced by repeated immunizations with raised against granulocytes of mouse origin.
Purity/Specificity:	Fluorescein conjugated Ly-6G/Ly-6C (Gr-1) Monoclonal Antibody was purified from tissue culture supernatant via affinity chromatography and is directed against mouse Ly-6G/Ly-6C (Gr-1). Cross reactivity with Ly-6G/Ly-6C (Gr-1) from other sources has not been tested. Anti-Ly-6G/Ly-6C (Gr-1) is conjugated with FITC under optimal conditions and the solution is free of unconjugated FITC.
Relevant Links:	• NCBI - NP_001238984.1 • GeneID - 17067

Application Details

Tested Applications:	FC, Multiplex
Application Note:	Anti-Ly-6G/Ly-6C (Gr-1) is tested for FLOW and useful for Immunohistochemistry, Immunoprecipitation, and Western Blot using mouse spleen cells, or an appropriate cell type (where indicated). Researchers should determine optimal titers for applications that are not stated.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
FC:	10 μ L/10 ⁶ cells (0.1 μ g)
IHC:	User Optimized
IP:	User Optimized
WB:	User Optimized

Formulation


Physical State:	Liquid (sterile filtered)
Concentration:	0.5mg/mL Sufficient to run approximately 100 tests
Buffer:	0.01 M Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.09% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Wet Ice
----------------------------	---------

Storage Condition:	Store vial at 4° C prior to opening. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use. DO NOT FREEZE. This product is light sensitive.
Expiration:	Expiration date is six (6) months from date of receipt.

Images



Flow Cytometry


Effects of isoform-specific and non-selective HDACIs on CLP-induced sepsis immune cell response. The spleens were homogenized into single-cell suspension and stained with anti-rat CD3, B220, CD11b, GR-1 and F4/80. Flow cytometry analysis was conducted on the different cell populations. Left representative of plots T lymphocytes, B lymphocytes, innate immune cells, macrophages and neutrophils are shown. Histograms on the right show relative changes in the indicated cell population. *P < 0.05, **P < 0.01 and ***P < 0.001 for significant differences between the treatment and VEH groups.

Sham: the peritoneal cavity was opened, but the cecum was eviscerated without ligated or punctured; VEH: vehicle; TubA: tubastatinA; TSA: trichostatin-A.

Fig 5. PMID: 36936452

Flow Cytometry

Flow Cytometry of anti-Ly-6G/Ly-6C (Gr-1) Fluorescein Conjugated Monoclonal Antibody. Cells: C57BL/6 mouse bone marrow. Stimulation: none. Antibody: CD11b PE and Fluorescein Anti-Ly-6G/Ly-6C (Gr-1) antibody (clone RB6-8C5).



References

- Niu K et al. Protective effect of HDACIs in improves survival and organ injury after CLP-induced sepsis. *Surg Open Sci.* (2023)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.